Literature DB >> 10644684

Erythrocytes possess an intrinsic barrier to nitric oxide consumption.

M W Vaughn1, K T Huang, L Kuo, J C Liao.   

Abstract

It has been reported that free hemoglobin (Hb) reacts with NO at an extremely high rate (K(Hb) approximately 10(7) M(-1) s(-1)) and that the red blood cell (RBC) membrane is highly permeable to NO. RBCs, however, react with NO 500-1000 times slower. This reduction of NO reaction rate by RBCs has been attributed to the extracellular diffusion limitation. To test whether additional limitations are also important, we designed a competition test, which allows the extracellular diffusion limitation to be distinguished from transmembrane or intracellular resistance. This test exploited the competition between free Hb and RBCs for NO generated in a homogenous phase by an NO donor. If the extracellular diffusion resistance is negligible, then the results would follow a kinetic model that assumes homogenous reaction without extracellular diffusion limitation. In this case, the measured effective reaction rate constant, K(RBC), would remain invariant of the hematocrit, extracellular-free Hb concentration, and NO donor concentration. Results show that the K(RBC) approaches a constant only when the hematocrit is greater than 10%, suggesting that at higher hematocrit, the extracellular diffusion resistance is negligible. Under such a condition, the NO consumption by RBCs is still 500-1000 times slower than that by free Hb. This result suggests that intrinsic RBC factors, such as transmembrane diffusion limitation or intracellular mechanisms, exist to reduce the NO consumption by RBCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644684     DOI: 10.1074/jbc.275.4.2342

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Evidence for in vivo transport of bioactive nitric oxide in human plasma.

Authors:  Tienush Rassaf; Michael Preik; Petra Kleinbongard; Thomas Lauer; Christian Heiss; Bodo-Eckehard Strauer; Martin Feelisch; Malte Kelm
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  NO solutions?

Authors:  Alan N Schechter; Mark T Gladwin; Richard O Cannon
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.

Authors:  I L Megson; N Sogo; F A Mazzei; A R Butler; J C Walton; D J Webb
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Regulation of nitric oxide consumption by hypoxic red blood cells.

Authors:  Tae H Han; Erion Qamirani; Allyson G Nelson; Daniel R Hyduke; Gautam Chaudhuri; Lih Kuo; James C Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

5.  Nitric oxide is consumed, rather than conserved, by reaction with oxyhemoglobin under physiological conditions.

Authors:  Mahesh S Joshi; T Bruce Ferguson; Tae H Han; Daniel R Hyduke; James C Liao; Tienush Rassaf; Nathan Bryan; Martin Feelisch; Jack R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

Review 6.  Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions.

Authors:  Andrea Mozzarelli; Luca Ronda; Serena Faggiano; Stefano Bettati; Stefano Bruno
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

7.  Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion.

Authors:  Kenji Sampei; John A Ulatowski; Yoshio Asano; Herman Kwansa; Enrico Bucci; Raymond C Koehler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-13       Impact factor: 4.733

8.  Connexin 36 mediates blood cell flow in mouse pancreatic islets.

Authors:  Kurt W Short; W Steve Head; David W Piston
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

Review 9.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

10.  Angeli's salt counteracts the vasoactive effects of elevated plasma hemoglobin.

Authors:  Steven B Solomon; Landon Bellavia; Daniel Sweeney; Barbora Piknova; Andreas Perlegas; Christine C Helms; Gabriela A Ferreyra; S Bruce King; Nicolaas J H Raat; Steven J Kern; Junfeng Sun; Linda C McPhail; Alan N Schechter; Charles Natanson; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  Free Radic Biol Med       Date:  2012-10-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.